Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - acidum acetylsalicylicum - filmtabletten - säure acetylsalicylicum 100 mg, excipiens pro compresso dunst. - thrombozytenaggregationshemmung: reinfarktprophylaxe, reokklusionsprophylaxe, unsicheren angina pectoris - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - acidum acetylsalicylicum - filmtabletten - acidum acetylsalicylicum 100 mg, cellulosum microcristallinum, maydis amylum, silica colloidalis anhydrica, acidum stearicum, Überzug: acidi methacrylici et ethylis acrylatis polymerisatum 1:1, polysorbatum 80, natrii laurilsulfas corresp. natrium 2 µg, triethylis citras, talcum pro compresso obducto. - thrombozytenaggregationshemmung: reinfarktprophylaxe, reokklusionsprophylaxe, unsicheren angina pectoris - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

axapharm ag - acidum acetylsalicylicum - magensaftresistente tabletten - acidum acetylsalicylicum 100 mg, lactosum monohydricum 60 mg, cellulosum microcristallinum, silica colloidalis anhydrica, solani amylum, Überzug: talcum, triacetinum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1 pro compresso obducto. - thrombozytenaggregationshemmung: reinfarktprophylaxe, reokklusionsprophylaxe, unsicheren angina pectoris - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antithrombotische mittel - xarelto, co-verabreicht mit acetylsalicylsäure (asa) allein oder mit ass plus clopidogrel oder ticlopidine, ist indiziert für die prävention von atherothrombotischen ereignissen bei erwachsenen patienten nach einem akuten koronarsyndrom (acs) mit erhöhten kardialen biomarkern. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prävention venöser thromboembolien (vte) bei erwachsenen patienten, die sich einer hüft- oder kniegelenksersatzoperation unterziehen. behandlung von tiefen venenthrombosen (tvt) und lungenembolie (pe) und prävention von wiederkehrenden dvt und pe bei erwachsenen. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Europäische Union - Deutsch - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotische mittel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

hexal pharma gmbh - acetylsalicylsÄure - acetylsalicylsäure

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

teva b.v. - acetylsalicylsÄure - acetylsalicylsäure

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

gsk-gebro consumer healthcare gmbh - acetylsalicylsÄure; coffein; paracetamol - acetylsalicylsäure, kom

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dr. pfleger arzneimittel gmbh - geschäftsanschrift - (3012937) - acetylsalicylsäure (ph.eur.) - tablette - 500.mg - acetylsalicylsäure (ph.eur.) (00002) 500 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dr. pfleger arzneimittel gmbh - geschäftsanschrift - (3012937) - acetylsalicylsäure (ph.eur.) - tablette - acetylsalicylsäure (ph.eur.) (00002) 500 milligramm